Neoadjuvant/adjuvant therapy for breast cancer

2013 ◽  
pp. 42-53
Author(s):  
Sarah DeSnyder
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy

Adjuvant Therapy of Breast Cancer

1994 ◽  
Vol 8 (1) ◽  
pp. 213-231 ◽  
Author(s):  
Charles L. Shapiro ◽  
I. Craig Henderson
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy

scholarly journals NCI monographs: I. Adjuvant therapy of breast cancer

Cancer ◽  
1987 ◽  
Vol 59 (11) ◽  
pp. 1983-1983
Author(s):  
Michael H. Torosian
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy

Adverse Vascular Functional and Structural Changes Secondary to Breast Cancer and its Treatments with Adjuvant Therapy: a Systematic Review

2021 ◽  
Author(s):  
Alis Bonsignore ◽  
Priya Brahmbhatt ◽  
Daniel Santa Mina ◽  
Jack Goodman ◽  
Maureen Pakosh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Structural Changes

scholarly journals Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2254
Author(s):  
Matteo Franchi ◽  
Roberta Tritto ◽  
Luigi Tarantini ◽  
Alessandro Navazio ◽  
Giovanni Corrao
Keyword(s):  
Breast Cancer ◽  
Heart Failure ◽  
Adjuvant Therapy ◽  
Large Population ◽  
Positive Association ◽  
Population Based ◽  
Study Cohort ◽  
Increased Risk ◽  
Post Menopausal ◽  
New Diagnosis

Background: Whether aromatase inhibitors (AIs) increase the risk of cardiovascular (CV) events, compared to tamoxifen, in women with breast cancer is still debated. We evaluated the association between AI and CV outcomes in a large population-based cohort of breast cancer women. Methods: By using healthcare utilization databases of Lombardy (Italy), we identified women ≥50 years, with new diagnosis of breast cancer between 2009 and 2015, who started adjuvant therapy with either AI or tamoxifen. We estimated the association between exposure to AI and CV outcomes (including myocardial infarction, ischemic stroke, heart failure or any CV event) by a Cox proportional hazard model with inverse probability of treatment and censoring weighting. Results: The study cohort included 26,009 women starting treatment with AI and 7937 with tamoxifen. Over a median follow-up of 5.8 years, a positive association was found between AI and heart failure (Hazard Ratio = 1.20, 95% CI: 1.02 to 1.42) and any CV event (1.14, 1.00 to 1.29). The CV risk increased in women with previous CV risk factors, including hypertension, diabetes and dyslipidemia. Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.

Sign in / Sign up

Export Citation Format

Share Document